201 related articles for article (PubMed ID: 30259989)
1. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
Honda K; Katzke VA; Hüsing A; Okaya S; Shoji H; Onidani K; Olsen A; Tjønneland A; Overvad K; Weiderpass E; Vineis P; Muller D; Tsilidis K; Palli D; Pala V; Tumino R; Naccarati A; Panico S; Aleksandrova K; Boeing H; Bueno-de-Mesquita HB; Peeters PH; Trichopoulou A; Lagiou P; Khaw KT; Wareham N; Travis RC; Merino S; Duell EJ; Rodríguez-Barranco M; Chirlaque MD; Barricarte A; Rebours V; Boutron-Ruault MC; Romana Mancini F; Brennan P; Scelo G; Manjer J; Sund M; Öhlund D; Canzian F; Kaaks R
Int J Cancer; 2019 Apr; 144(8):1877-1887. PubMed ID: 30259989
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.
Kashiro A; Kobayashi M; Oh T; Miyamoto M; Atsumi J; Nagashima K; Takeuchi K; Nara S; Hijioka S; Morizane C; Kikuchi S; Kato S; Kato K; Ochiai H; Obata D; Shizume Y; Konishi H; Nomura Y; Matsuyama K; Xie C; Wong C; Huang Y; Jung G; Srivastava S; Kutsumi H; Honda K
J Gastroenterol; 2024 Mar; 59(3):263-278. PubMed ID: 38261000
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.
Hayasaki A; Murata Y; Usui M; Hibi T; Fujii T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Uchida K; Isaji S
Biomed Res Int; 2019; 2019():5738614. PubMed ID: 31080824
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
[TBL] [Abstract][Full Text] [Related]
5. Serum apolipoprotein A2 isoforms in autoimmune pancreatitis.
Kobayashi T; Sato Y; Nishiumi S; Yagi Y; Sakai A; Shiomi H; Masuda A; Okaya S; Kutsumi H; Yoshida M; Honda K
Biochem Biophys Res Commun; 2018 Mar; 497(3):903-907. PubMed ID: 29481802
[TBL] [Abstract][Full Text] [Related]
6. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
Honda K; Kobayashi M; Okusaka T; Rinaudo JA; Huang Y; Marsh T; Sanada M; Sasajima Y; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Miura N; Kamita M; Sakamoto T; Shoji H; Jung G; Srivastava S; Yamada T
Sci Rep; 2015 Nov; 5():15921. PubMed ID: 26549697
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms.
Honda K
Cancer Biomark; 2022; 33(4):503-512. PubMed ID: 35491769
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein A2 Isoforms in Relation to the Risk of Myocardial Infarction: A Nested Case-Control Analysis in the JPHC Study.
Kihara T; Yamagishi K; Honda K; Ikeda A; Yatsuya H; Saito I; Kokubo Y; Yamaji T; Shimazu T; Sawada N; Iwasaki M; Iso H; Tsugane S;
J Atheroscler Thromb; 2021 May; 28(5):483-490. PubMed ID: 32863295
[TBL] [Abstract][Full Text] [Related]
9. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer.
Sato Y; Kobayashi T; Nishiumi S; Okada A; Fujita T; Sanuki T; Kobayashi M; Asahara M; Adachi M; Sakai A; Shiomi H; Masuda A; Yoshida M; Takeuchi K; Kodama Y; Kutsumi H; Nagashima K; Honda K
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32937962
[TBL] [Abstract][Full Text] [Related]
10. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
Fahrmann JF; Schmidt CM; Mao X; Irajizad E; Loftus M; Zhang J; Patel N; Vykoukal J; Dennison JB; Long JP; Do KA; Zhang J; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger J; Yip-Schneider MT; Maitra A; Wolpin BM; Hanash S
Gastroenterology; 2021 Mar; 160(4):1373-1383.e6. PubMed ID: 33333055
[TBL] [Abstract][Full Text] [Related]
11. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
12. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
[TBL] [Abstract][Full Text] [Related]
13. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein A2 isoforms associated with exocrine pancreatic insufficiency in early chronic pancreatitis.
Futagami S; Agawa S; Nakamura K; Watanabe Y; Habiro M; Kawawa R; Yamawaki H; Tsushima R; Kirita K; Akimoto T; Ueki N; Tomohide T; Itokawa N; Suzuki N; Naito Y; Takeuchi K; Kashiro A; Ohta R; Mizutani S; Taniai N; Yoshida H; Iwakiri K; Honda K
J Gastroenterol Hepatol; 2023 Nov; 38(11):1949-1957. PubMed ID: 37501507
[TBL] [Abstract][Full Text] [Related]
15. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
16. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 for detecting recurrence of pancreatic cancer.
Azizian A; Rühlmann F; Krause T; Bernhardt M; Jo P; König A; Kleiß M; Leha A; Ghadimi M; Gaedcke J
Sci Rep; 2020 Jan; 10(1):1332. PubMed ID: 31992753
[TBL] [Abstract][Full Text] [Related]
18. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
19. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
